Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. iRobot Corporation
23% sales growth and 21.89% return on equity
iRobot Corporation designs, builds, and sells robots to the consumer market in the United States, Europe, the Middle East, Africa, and internationally.
iRobot Corporation sales growth this year is expected to be 12.9% and 7.3% for next year.
Year-on-year quarterly revenue growth grew by 42.8%, now sitting on 1.31B for the twelve trailing months.
iRobot Corporation's sales growth for the next quarter is 23%. The company's growth estimates for the present quarter and the next is a negative 70% and 75%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.89%.
iRobot Corporation's Stock Top and Bottom Yearly Value
iRobot Corporation's stock is valued at $78.32 at 08:34 EST, way below its 52-week high of $98.55 and way higher than its 52-week low of $32.79.
iRobot Corporation's Moving Average
iRobot Corporation's worth is below its 50-day moving average of $82.33 and higher than its 200-day moving average of $78.28.
2. Seattle Genetics, Inc.
60.8% sales growth and 23.4% return on equity
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Seattle Genetics, Inc. sales growth this year is expected to be 134.9% and a negative 16.8% for next year.
Year-on-year quarterly revenue growth grew by 397.9%, now sitting on 1.86B for the twelve trailing months.
Seattle Genetics, Inc.'s sales growth for the next quarter is 60.8%. The company's growth estimates for the ongoing quarter and the next is 478.6% and 72.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.4%.
Seattle Genetics, Inc.'s Stock Top and Bottom Yearly Value
Seattle Genetics, Inc.'s stock is valued at $168.72 at 08:34 EST, way below its 52-week high of $213.94 and way above its 52-week low of $90.57.
Seattle Genetics, Inc.'s Moving Average
Seattle Genetics, Inc.'s worth is below its 50-day moving average of $184.82 and below its 200-day moving average of $170.56.
3. MEDIFAST INC
42.6% sales growth and 75.43% return on equity
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.
MEDIFAST INC sales growth this year is expected to be 28.8% and 19.5% for next year.
Year-on-year quarterly revenue growth grew by 42.8%, now sitting on 840.56M for the twelve trailing months.
MEDIFAST INC's sales growth for the next quarter is 42.6%. The company's growth estimates for the present quarter and the next is 45.8% and 37.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 75.43%.
MEDIFAST INC's Stock Top and Bottom Yearly Value
MEDIFAST INC's stock is valued at $193.43 at 08:34 EST, under its 52-week high of $196.37 and way above its 52-week low of $49.03.
MEDIFAST INC's Moving Average
MEDIFAST INC's worth is way higher than its 50-day moving average of $161.46 and way higher than its 200-day moving average of $148.61.
4. Green Brick Partners, Inc.
62.3% sales growth and 18.09% return on equity
Green Brick Partners, Inc. operates as a homebuilding and land development company in the United States.
Green Brick Partners, Inc. sales growth this year is anticipated to be 25.9% and 35.4% for next year.
Year-on-year quarterly revenue growth grew by 31.7%, now sitting on 952.04M for the twelve trailing months.
Green Brick Partners, Inc.'s sales growth for the next quarter is 62.3%. The company's growth estimates for the ongoing quarter and the next is 103.2% and 83.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.09%.
Green Brick Partners, Inc.'s Stock Top and Bottom Yearly Value
Green Brick Partners, Inc.'s stock is valued at $22.92 at 08:34 EST, below its 52-week high of $25.05 and way above its 52-week low of $5.66.
Green Brick Partners, Inc.'s Moving Average
Green Brick Partners, Inc.'s worth is way above its 50-day moving average of $20.04 and way above its 200-day moving average of $15.18.
5. Sapiens International Corporation N.V.
15.6% sales growth and 13.91% return on equity
Sapiens International Corporation N.V.
Sapiens International Corporation N.V. sales growth this year is expected to be 17.3% and 10.2% for next year.
Year-on-year quarterly revenue growth grew by 18.2%, now sitting on 367.96M for the twelve trailing months.
Sapiens International Corporation N.V.'s sales growth for the next quarter is 15.6%. The company's growth estimates for the current quarter and the next is 19% and 20%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.91%.
Sapiens International Corporation N.V.'s Stock Top and Bottom Yearly Value
Sapiens International Corporation N.V.'s stock is valued at $29.89 at 08:34 EST, way below its 52-week high of $35.23 and way above its 52-week low of $13.55.
Sapiens International Corporation N.V.'s Moving Average
Sapiens International Corporation N.V.'s worth is higher than its 50-day moving average of $29.38 and higher than its 200-day moving average of $29.23.
6. Stewart Information Services Corporation
15.6% sales growth and 12.67% return on equity
Stewart Information Services Corporation, through its subsidiaries, provides title insurance and real estate transaction services.
Stewart Information Services Corporation sales growth this year is anticipated to be 11.3% and 2.9% for next year.
Year-on-year quarterly revenue growth declined by 2.3%, now sitting on 2.01B for the twelve trailing months.
Stewart Information Services Corporation's sales growth for the next quarter is 15.6%. The company's growth estimates for the present quarter and the next is 111.3% and 25%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.67%.
Stewart Information Services Corporation's Stock Top and Bottom Yearly Value
Stewart Information Services Corporation's stock is valued at $44.10 at 08:34 EST, way below its 52-week high of $49.48 and way above its 52-week low of $20.26.
Stewart Information Services Corporation's Moving Average
Stewart Information Services Corporation's value is under its 50-day moving average of $44.52 and way higher than its 200-day moving average of $39.14.
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
